Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

The effects of various agents targeting these gastrointestinal peptide systems, as shown in preclinical studies, are compared in Table 1. Enough experience from large clinical trials has been ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

such as glucagon-like peptide-1, free fatty acids, and catecholamines. With this knowledge, scientists are seeking to better understand the role of GPCRs in islet biology and hormone secretion ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

For example, the company is developing an NIPEP-TPP anti-mutant KRAS antibody that binds the G12C mutant form of the human KRAS ... hormone (PTH) or glucagon-like peptide-1 (GLP-1) receptor ...

Though it could have lots of use cases in the future, Phytogene's first order of business is synthesizing glucagon-like ...